NewAmsterdam Pharma (NAMS) Competitors $24.90 -0.07 (-0.28%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NAMS vs. ITCI, ROIV, ASND, LEGN, ELAN, CYTK, BPMC, NUVL, VKTX, and LNTHShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Blueprint Medicines (BPMC), Nuvalent (NUVL), Viking Therapeutics (VKTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Cytokinetics Blueprint Medicines Nuvalent Viking Therapeutics Lantheus Intra-Cellular Therapies (NASDAQ:ITCI) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk. Does the MarketBeat Community prefer ITCI or NAMS? Intra-Cellular Therapies received 503 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 67.84% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% NewAmsterdam PharmaOutperform Votes18100.00% Underperform VotesNo Votes Do analysts prefer ITCI or NAMS? Intra-Cellular Therapies currently has a consensus target price of $97.23, indicating a potential upside of 16.56%. NewAmsterdam Pharma has a consensus target price of $33.80, indicating a potential upside of 35.74%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ITCI or NAMS? Intra-Cellular Therapies has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Which has higher earnings & valuation, ITCI or NAMS? Intra-Cellular Therapies has higher revenue and earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$464.37M19.05-$139.67M-$0.87-95.88NewAmsterdam Pharma$33.59M66.72-$176.94MN/AN/A Is ITCI or NAMS more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. NewAmsterdam Pharma's return on equity of 0.00% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% NewAmsterdam Pharma N/A N/A N/A Does the media favor ITCI or NAMS? In the previous week, NewAmsterdam Pharma had 8 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 19 mentions for NewAmsterdam Pharma and 11 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 1.21 beat NewAmsterdam Pharma's score of 0.57 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in ITCI or NAMS? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryNewAmsterdam Pharma beats Intra-Cellular Therapies on 9 of the 16 factors compared between the two stocks. Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.24B$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E RatioN/A10.92101.9117.46Price / Sales66.72244.561,195.1369.04Price / CashN/A53.4941.0436.36Price / Book5.919.306.345.87Net Income-$176.94M$154.14M$119.64M$225.66M7 Day Performance3.23%-9.47%-5.13%-1.34%1 Month Performance30.85%-7.30%-2.72%1.15%1 Year Performance163.49%28.21%31.10%24.02% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.0131 of 5 stars$24.90-0.3%$33.80+35.7%+150.5%$2.24B$33.59M0.0057Short Interest ↑News CoverageHigh Trading VolumeITCIIntra-Cellular Therapies4.5093 of 5 stars$83.42-4.8%N/A+51.6%$8.84B$464.37M-95.88560Insider SellingPositive NewsROIVRoivant Sciences3.419 of 5 stars$11.20-3.8%N/A+24.2%$8.28B$129.13M1.98860Analyst ForecastNews CoverageASNDAscendis Pharma A/S3.0537 of 5 stars$126.51+1.8%N/A+35.3%$7.67B$288.08M-13.59640Analyst DowngradeShort Interest ↑News CoverageGap DownHigh Trading VolumeLEGNLegend Biotech1.8575 of 5 stars$38.19-4.3%N/A-39.9%$6.96B$455.99M-40.201,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeELANElanco Animal Health3.5205 of 5 stars$13.98-0.4%N/A+21.5%$6.91B$4.42B34.959,300Short Interest ↑CYTKCytokinetics4.0656 of 5 stars$50.22-8.2%N/A+58.5%$5.93B$3.22M-9.33250Insider SellingBPMCBlueprint Medicines3.0721 of 5 stars$88.69-7.3%N/A+41.6%$5.63B$249.38M-42.03640Analyst ForecastShort Interest ↑News CoverageNUVLNuvalent3.1096 of 5 stars$86.88-3.7%N/A+49.7%$5.63BN/A-25.0440Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageVKTXViking Therapeutics4.5045 of 5 stars$49.58-7.4%N/A+370.8%$5.53BN/A-53.3120LNTHLantheus4.6047 of 5 stars$76.83-5.0%N/A+12.7%$5.34B$1.30B12.78834 Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Blueprint Medicines Alternatives Nuvalent Alternatives Viking Therapeutics Alternatives Lantheus Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NAMS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMS Stock Alerts